
Evotec and BMS enter drug discovery licence agreement
Evotec and Bristol Myers Squibb (BMS) have entered into an exclusive global licence agreement, extending their neuroscience partnership. The agreement covers selected late-stage discovery programmes that were developed and progressed within the collaboration between the two companies. Evotec and BMS originally entered their neurodegeneration… Read More

